Uveitis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 13,320 adverse event reports that record the MedDRA preferred term Uveitis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 1,059 reports in the 12 months to June 2026 and 1,074 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 583 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 1,059 (0.1%) record this term. Reports for patients aged 18 to 44 were 17.5% of the reports that record this term and 12.3% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 132 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Uveitis name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	45
Abrilada		63
Aclasta		37
Actemra	Interleukin-6 receptor antagonist	142
Adalimumab	Tumor necrosis factor blocker	539
Aflibercept	Vascular endothelial growth factor inhibitor	40
Amphotericin b	Lipid-based polyene antifungal	68
Arava	Antirheumatic agent	38
Atezolizumab	Programmed death Receptor-1 blocking antibody	26
Avastin	Vascular endothelial growth factor inhibitor	200
Avelox		51
Avonex	Interferon beta	28
Azathioprine	Purine antimetabolite	95
Beovu		309
Bevacizumab	Vascular endothelial growth factor inhibitor	95
Bimekizumab		29
Braftovi		61
Brolucizumab		48
Carboplatin	Platinum-based drug	33
Ceftazidime	Cephalosporin antibacterial	60
Celebrex	Nonsteroidal anti-inflammatory drug	68
Celecoxib	Nonsteroidal anti-inflammatory drug	29
CellCept	Antimetabolite immunosuppressant	26
Certolizumab pegol	Tumor necrosis factor blocker	91
Ciclosporin		35
Cimzia	Tumor necrosis factor blocker	187
Ciprofloxacin	Fluoroquinolone antibacterial	52
Clarithromycin	Macrolide antimicrobial	25
Cobimetinib	Kinase inhibitor	29
Colchicine	Alkaloid	31
Colistin		61
Corticotropin		42
Cosentyx	Interleukin-17A antagonist	556
Cotellic	Kinase inhibitor	26
Cyclophosphamide	Alkylating drug	36
Cyclosporine	Calcineurin inhibitor immunosuppressant	86
Dabrafenib	Kinase inhibitor	110
Dexamethasone	Corticosteroid	82
Diclofenac	Nonsteroidal anti-inflammatory drug	118
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	43
Dupixent	Interleukin-4 receptor alpha antagonist	86
Enbrel	Tumor necrosis factor blocker	930
Entyvio	Integrin receptor antagonist	45
Erelzi		70
Etanercept	Tumor necrosis factor blocker	186
Eylea	Vascular endothelial growth factor inhibitor	312
Eylea Hd	Vascular endothelial growth factor inhibitor	38
Faricimab		34
Gilenya	Sphingosine 1-phosphate receptor modulator	78
Golimumab	Tumor necrosis factor blocker	68
Hulio		38
Humira		1,797
Hydroxychloroquine	Antimalarial	107
Hydroxychloroquine sulfate	Antimalarial	65
Hyrimoz	Tumor necrosis factor blocker	144
Ibuprofen	Nonsteroidal anti-inflammatory drug	51
Imbruvica	Kinase inhibitor	107
Imraldi		31
Inflectra	Tumor necrosis factor blocker	720
Infliximab	Tumor necrosis factor blocker	788
Infliximab Recombinant		71
Ipilimumab	CTLA-4-directed blocking antibody	112
Ixifi		53
Keytruda	Programmed death Receptor-1 blocking antibody	84
Leflunomide	Antirheumatic agent	138
Linezolid	Oxazolidinone antibacterial	73
Lucentis	Vascular endothelial growth factor inhibitor	125
Maxidex	Corticosteroid	58
Mekinist	Kinase inhibitor	133
Mektovi		54
Methotrexate	Folate analog metabolic inhibitor	752
Methotrexate sodium	Folate analog metabolic inhibitor	244
Methylprednisolone	Corticosteroid	50
Moxifloxacin	Fluoroquinolone antibacterial	52
Moxifloxacin hydrochloride	Fluoroquinolone antibacterial	44
Mycophenolate mofetil	Antimetabolite immunosuppressant	227
Myochrysine		27
Naproxen	Nonsteroidal anti-inflammatory drug	70
Nivolumab	Programmed death Receptor-1 blocking antibody	181
Norvir	Cytochrome P450 3A inhibitor	29
Opdivo	Programmed death Receptor-1 blocking antibody	189
Orencia	Selective T cell costimulation modulator	122
Otezla	Phosphodiesterase 4 inhibitor	55
Ozurdex	Corticosteroid	50
Paclitaxel	Microtubule inhibitor	32
Pembrolizumab	Programmed death Receptor-1 blocking antibody	67
Piperacillin sodium,tazobactam sodium		27
Plaquenil	Antimalarial	39
Prednisolone	Corticosteroid	157
Prednisolone acetate	Corticosteroid	43
Prednisolone sodium phosphate	Corticosteroid	55
Prednisone	Corticosteroid	387
Prolia	RANK ligand inhibitor	37
Ramipril	Angiotensin converting enzyme inhibitor	26
Ranibizumab	Vascular endothelial growth factor inhibitor	27
Reclast	Bisphosphonate	44
Remicade	Tumor necrosis factor blocker	595
Ribavirin	Nucleoside analog antiviral	27
Rifabutin		54
Rinvoq	Janus kinase inhibitor	50
Rituxan	CD20-directed cytolytic antibody	36
Rituximab	CD20-directed cytolytic antibody	172
Secukinumab	Interleukin-17A antagonist	86
Simbrinza	Carbonic anhydrase inhibitor	48
Simponi	Tumor necrosis factor blocker	318
Skyrizi	Interleukin-23 antagonist	31
Stelara	Interleukin-12 antagonist	103
Sulfasalazine	Aminosalicylate	182
Syfovre	Complement inhibitor	73
Tacrolimus	Calcineurin inhibitor immunosuppressant	112
Tafinlar	Kinase inhibitor	146
TobraDex	Aminoglycoside antibacterial	38
Tobramycin	Aminoglycoside antibacterial	57
Tocilizumab	Interleukin-6 receptor antagonist	136
Tofacitinib	Janus kinase inhibitor	27
Topiramate		56
Trametinib	Kinase inhibitor	99
Triamcinolone		36
Triamcinolone acetonide	Corticosteroid	36
Tysabri	Integrin receptor antagonist	38
Ustekinumab	Interleukin-12 antagonist	28
Vabysmo		301
Vancomycin	Glycopeptide antibacterial	47
Vancomycin hydrochloride	Glycopeptide antibacterial	30
Vedolizumab	Integrin receptor antagonist	184
Vemurafenib	Kinase inhibitor	56
Voriconazole	Azole antifungal	65
Xeljanz	Janus kinase inhibitor	141
Yervoy	CTLA-4-directed blocking antibody	116
Zelboraf	Kinase inhibitor	58
Zoledronic acid	Bisphosphonate	65
Zometa		25

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 60 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Uveitis name, in order of name
Class	Reports with this term
Alkaloid	31
Alkylating drug	46
alpha-Adrenergic agonist	42
Aminoglycoside antibacterial	95
Aminosalicylate	190
Angiotensin converting enzyme inhibitor	35
Anti-epileptic agent	25
Antimalarial	211
Antimetabolite immunosuppressant	262
Antimycobacterial	35
Antirheumatic agent	176
Aromatase inhibitor	44
Azole antifungal	82
beta-Adrenergic blocker	41
Bisphosphonate	170
Calcineurin inhibitor immunosuppressant	223
Carbonic anhydrase inhibitor	60
CD20-directed cytolytic antibody	257
Cephalosporin antibacterial	86
Complement inhibitor	78
Corticosteroid	929
CTLA-4-directed blocking antibody	230
Cytochrome P450 3A inhibitor	42
Dihydrofolate reductase inhibitor antibacterial	27
Fluoroquinolone antibacterial	184
Folate analog metabolic inhibitor	1,004
Glycopeptide antibacterial	77
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	35
HMG-CoA reductase inhibitor	34
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	37
Integrin receptor antagonist	267
Interferon beta	48
Interleukin-12 antagonist	131
Interleukin-17A antagonist	676
Interleukin-23 antagonist	44
Interleukin-4 receptor alpha antagonist	105
Interleukin-6 receptor antagonist	302
Janus kinase inhibitor	252
Kinase inhibitor	880
Lipid-based polyene antifungal	68
Macrolide antimicrobial	37
Microtubule inhibitor	32
Nonsteroidal anti-inflammatory drug	486
Nucleoside analog antiviral	27
Nucleoside metabolic inhibitor	29
Opioid agonist	26
Oxazolidinone antibacterial	73
Penicillin-class antibacterial	25
Phosphodiesterase 4 inhibitor	63
Platinum-based drug	58
Programmed death Receptor-1 blocking antibody	556
Prostaglandin analog	43
Proton pump inhibitor	63
Purine antimetabolite	119
RANK ligand inhibitor	42
Selective T cell costimulation modulator	167
Serotonin reuptake inhibitor	39
Sphingosine 1-phosphate receptor modulator	87
Tumor necrosis factor blocker	4,615
Vascular endothelial growth factor inhibitor	839

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Uveitis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Uveitis
Age	Reports	Share
Under 2	13	0.1%
2 to 11	324	2.4%
12 to 17	319	2.4%
18 to 44	2,335	17.5%
45 to 64	2,978	22.4%
65 to 74	1,261	9.5%
75 and over	897	6.7%
Age not given	5,193	39%

Sex of the patient in the reports that record Uveitis
Sex	Reports	Share
Female	6,695	50.3%
Male	4,015	30.1%
Unknown or not given	2,610	19.6%

Age and sex are as the report gives them. 28.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Uveitis: adverse event reports that record this term. https://reportedreactions.com/reaction/uveitis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Uveitis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page